Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations

Novartis Pharmaceuticals

Overview

A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.

Study Type

OBSERVATIONAL

Conditions

Asthma

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥12 years of age with a documented Cystic fibrosis (CF) diagnosis, * on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline, * uncontrolled asthma at baseline. Exclusion Criteria: Other protocol-defined inclusion/exclusion criteria may apply.

Outcomes

Primary Outcomes

Frequency of emergency-department visits and hospitalizations

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.